Opus Genetics vs Xenon Pharmaceuticals
IRD and XENE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IRD and XENE compare
Xenon Pharmaceuticals is the larger company, worth 11 times as much as Opus Genetics ($4.1B against $359M).
Opus Genetics grew revenue faster over the last twelve months (−45.9% versus −100% for Xenon Pharmaceuticals).
Xenon Pharmaceuticals scores higher on the StockData Score (7 against 5 for Opus Genetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IRD | XENE |
|---|---|---|
| Size and price | ||
| Market cap | $359M | $4.1B |
| Share price | $4.31 | $42.10 |
| Change, 1 year | 119% | 9.6% |
| Change, 5 years | 18.4% | 45.2% |
| Beta (5Y) | 0.98 | 0.63 |
| Employees | 27 | 370 |
| StockData Score | ||
| Total score | 5 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 4 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 45.3× | – |
| P/B | 9.3× | 3.6× (better) |
| FCF yield | – | −8.8% |
| Fair value | $0.739 | – |
| Margin of safety | −483% | – |
| Growth | ||
| Revenue growth (TTM) | −45.9% (better) | −100% |
| Revenue growth, 5Y average | – | −25.3% |
| Profitability | ||
| Operating margin | −778% | – |
| Net margin | −1727% | – |
| Return on equity | −616% | −50.3% (better) |
| Return on invested capital | – | −251% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −217.5× | – |
| Current ratio | 9.65 | 21.19 (better) |
| Altman Z-score | −1.73 | 43.53 (better) |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | −0.68% | – |
| Shareholder yield | −0.68% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 72.8% | 104% |
| Held by insiders | 37.6% | 0.17% |
| Insider net buying, 12 months | −$19.4M (better) | −$20.3M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 20.9% | 7.6% |
Go deeper
- IRD stock overview
- IRD income statement
- IRD valuation and score
- XENE stock overview
- XENE income statement
- XENE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.